71 filings
Page 3 of 4
6-K
mgcp8adyq7vsimup
13 Dec 21
Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies
6:10am
6-K
1pcu6ew3
30 Nov 21
Molecular Partners Confirms Retained Activity of Ensovibep on the Positions Mutated in Emerging Omicron Variant of SARS-CoV-2 In Vitro
6:10am
6-K
xteukh1hsexz
16 Nov 21
Molecular Partners Provides Update from ACTIV-3 Global Clinical Study of Ensovibep in Patients Hospitalized with COVID-19
6:10am
6-K
b0cyq2w0yw2x tfmdkr8
28 Oct 21
Current report (foreign)
6:11am
6-K
zjynwp30vb1t8c7h1
26 Aug 21
Molecular Partners Reports Corporate Highlights and Key Financials for H1 2021
6:10am
6-K
a8z0vj5g
9 Aug 21
Molecular Partners to Regain Global Rights to Abicipar
6:05am
6-K
mpc yo8yv26
8 Jul 21
Current report (foreign)
9:17am
424B4
pcf4p psdg
16 Jun 21
Prospectus supplement with pricing info
5:23pm
EFFECT
zwemut30
16 Jun 21
Notice of effectiveness
12:15am
EFFECT
vs4gx pko5su6uy
16 Jun 21
Notice of effectiveness
12:15am
SEC STAFF
6763bj
16 Jun 21
SEC staff action: Order
12:00am
CERT
wb9hmnspwxj5im t60a
15 Jun 21
Certification of approval for exchange listing
10:17am
F-1/A
6uiorcnxratur3o4c0qo
14 Jun 21
Registration statement (foreign) (amended)
9:08am
FWP
vcds0ocx
14 Jun 21
Free writing prospectus
9:06am
8-A12B
1tcrii
11 Jun 21
Registration of securities on exchange
4:03pm
CORRESP
88k ntnrbl
11 Jun 21
Correspondence with SEC
12:00am
CORRESP
jj1g xork
11 Jun 21
Correspondence with SEC
12:00am
F-1/A
145g9z0niv
10 Jun 21
Registration statement (foreign) (amended)
5:04pm
CORRESP
65c hcxcfp1
10 Jun 21
Correspondence with SEC
12:00am
F-6
oyfyjh 8b
9 Jun 21
Registration for ADRs (foreign)
12:01pm